Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies

NCT02013804 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT02013804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02013804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
Lead sponsor
MedImmune LLC
Phase
Phase 1
Overall status
Completed
Start date
December 19, 2013
Completion date
May 18, 2017
Enrollment
58 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies